Approval · Notice of Compliance 24117 · 2024
SIMVASTATIN: Notice of Compliance 24117
Issued May 16, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 24117
- Date
- May 16, 2024
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- ZOCOR (Merck Frosst Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMVASTATIN | 02284723 | Marketed |
| SIMVASTATIN | 02284731 | Marketed |
| SIMVASTATIN | 02284758 | Marketed |
| SIMVASTATIN | 02284766 | Marketed |
| SIMVASTATIN | 02284774 | Marketed |
Medicinal ingredients
- SIMVASTATIN 5 MG per TAB
- SIMVASTATIN 10 MG per TAB
- SIMVASTATIN 20 MG per TAB
- SIMVASTATIN 40 MG per TAB
- SIMVASTATIN 80 MG per TAB